Reply: Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C.
Infections and Immunoepidemiology Branch.
Thomas R
TR
O'Brien
Biostatistics Branch, Division of Cancer Epidemiology and Genetics , National Cancer Institute , Bethesda, Maryland.
Ruth M
RM
Pfeiffer